Exparel Approval History

• FDA approved: Yes (First approved October 28th, 2011)
• Brand name: Exparel
• Generic name: bupivacaine
• Company: Pacira Pharmaceuticals, Inc.
• Treatment for: Pain

Exparel (bupivacaine liposome injectable suspension) is a long-acting non-opioid local analgesic for the management of postsurgical pain.

FDA Approval History for Exparel

Date	Article
Oct 31, 2011	Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of Exparel For Postsurgical Pain Management
Jun 14, 2011	Pacira Pharmaceuticals, Inc. Announces FDA Extension of Exparel PDUFA Target Date By Three Months
Dec 14, 2010	Pacira Pharmaceuticals Announces FDA Acceptance of Exparel New Drug Application for Pain Management

See also...

Exparel (bupivacaine) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.